^
Association details:
| Biomarker: | PGP overexpression |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | Mepact (mifamurtide) (Macrophage stimulant, Monocyte stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials.
Published date:
05/19/2021
Excerpt:
Patients ≤ 40 years with extremity non-metastatic high-grade osteosarcoma were eligible....In case of Pgp overexpression (Pgp+), mifamurtide (2 mg/m2 twice/week for 3 months then weekly for 6 months) was added after surgery, with 4 consecutive cycles of ifosfamide 3 gr/m2/day, day 1-5 (HDIFO)...the 3-year EFS and OS were 71.9% (95%CI 66-76.9) and 88% (95%CI: 83.2-91.5) respectively, with no inferior survival for Pgp positive patients and improved survival for good responders...
Secondary therapy:
ifosfamide
DOI:
10.1200/JCO.2021.39.15_suppl.11527
